rosopatamab
aikido pharmaceuticals
['prostate', 'conv01']
today convergent announced details of a plenary presentation highlighting results of a dose-escalation study evaluating the efficacy and safety of its lead asset, conv01- in #prostatecancer patients at #aacr23. read the news release here: 
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer.